Survivors of childhood cancer who follow a healthy lifestyle may substantially reduce excess risk of later mortality from causes such as cancer and cardiovascular disease, suggests a new analysis.
Date Time
Excellent outcomes reported for first targeted frontline therapy for high-risk pediatric Hodgkin lymphoma
(From left) First and corresponding author Monika Metzger, M.D., Departments of Oncology and Global Pediatric Medicine; co- senior author Matthew Krasin, M.D., Department of Radiation Oncology; and co-senior author Melissa Hudson, M.D., Cancer Survivorship Division director.
Scientists are reporting results of the first frontline clinical trial to use targeted therapy to treat high-risk pediatric Hodgkin lymphoma. The study showed that the addition of brentuximab vedotin achieved excellent outcomes, reduced side effects, and allowed for reduced radiation exposures.
The study was the result of work by a multi-site consortium dedicated to pediatric Hodgkin-lymphoma. Collaborating institutions include St. Jude Children’s Research Hospital, Stanford University School of Medicine, Dana-Farber Cancer Institute, Massachusetts General Hospital, Maine Children’s Cancer P